Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle

Open access
Pinal‐Fernandez, Iago, Parks, Cassie, Werner, Jessie L., Albayda, Jemima, Paik, Julie J., Danoff, Sonye K., Casciola‐Rosen, Livia, Christopher‐Stine, Lisa, Mammen, Andrew L. · 2017 · Arthritis Care & Research

Abstract

Objective: Patients with immune‐mediated necrotizing myopathy (IMNM) often have autoantibodies recognizing the signal recognition particle (SRP) or HMG‐CoA reductase (HMGCR). Here, we studied a cohort of anti‐SRP patients to identify factors associated with disease severity and clinical improvement; we also compared the severity of weakness in those with anti‐SRP versus anti‐HMGCR autoantibodies. Methods: All anti‐SRP patients in the Johns Hopkins Myositis Cohort from 2002 to 2015 were included. Longitudinal information regarding proximal muscle strength, creatine kinase (CK) levels, and immunosuppressive therapy was recorded at each visit. Univariate and multivariate multilevel regression models were used to assess prognostic factors influencing recovery. Strength in the anti‐SRP patients was compared to strength in 49 previously described anti‐HMGCR subjects. Results: Data from 37 anti‐SRP patients and 380 total clinic visits were analyzed. Younger age at onset was associated with more severe weakness at the first visit (P = 0.02) and all subsequent visits (P = 0.002). Only 50% of patients reached near‐full or full strength after 4 years of treatment, and most of these continued to have elevated CK levels. Rituximab appeared to be effective in 13 of 17 anti‐SRP patients. Anti‐SRP patients were significantly weaker than those with anti‐HMGCR autoantibodies (−1.3 strength points; P = 0.001). Conclusion: Younger age at onset is associated with more severe weakness in anti‐SRP myositis. Furthermore, even among anti‐SRP patients whose strength improved with immunosuppression, most had ongoing disease activity as demonstrated by elevated CK levels. Finally, anti‐SRP patients were significantly weaker than anti‐HMGCR patients, providing evidence that these autoantibodies are associated with distinct forms of IMNM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acr.22920

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 167

Metadata

Authors
Pinal‐Fernandez, I., Parks, C., Werner, J. L., Albayda, J., Paik, J. J., Danoff, S. K., Casciola‐Rosen, L., Christopher‐Stine, L., & Mammen, A. L.
Venue
Arthritis Care & Research
Publisher
Wiley
Published
2016-12-31
Volume
69
Issue
2
Pages
263-270
ISSN
  • 0893-7524 (ISSN-L)
  • 2151-464X
  • 2151-4658
OpenAlex
W2344430242
Cited by
167
References
1
FWCI
12.27
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.